A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)

What is the purpose of this trial?

The purpose of this study is to determine whether Nivolumab is effective in the treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)



Bristol-Myers Squibb Company

Dates: 09/01/2017 - 07/01/2018

Last Updated: 09/03/2017

Study HIC#: 2000020850

Get Involved

For more information about this study, contact:
Tenzin Choezom
203-785-3865
t.choezom@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Kevin Patrick Becker

Principal Investigator

Sub-Investigators